Abstract：
Ophthalmic treatment demands precision and consistency in delivering therapeutic agents over extended periods to address many conditions, from common eye disorders to complex diseases. This diversity necessitates a range of delivery strategies, each tailored to specific needs. We delve into various delivery cargos that are pivotal in ophthalmic care. These cargos encompass biodegradable implants that gradually release medication, nonbiodegradable implants for sustained drug delivery, refillable tools allowing flexibility in treatment, hydrogels capable of retaining substances while maintaining ocular comfort, and advanced nanotechnology devices that precisely target eye tissues. Within each cargo category, we explore cutting-edge research-level approaches and FDA-approved methods, providing a thorough overview of the current state of ophthalmic drug delivery. In particular, our focus on nanotechnology reveals the promising potential for gene delivery, cell therapy administration, and the implantation of active devices directly into the retina. These advancements hold the key to more effective, personalized, and minimally- invasive ophthalmic treatments, revolutionizing the field of eye care.
摘要：
眼科治疗需要在长时间内提供治疗剂的精确性和一致性，以解决许多问题。从常见的眼部疾病到复杂的疾病。条件的多样性需要一系列的交付策略，每个人都适合特定的需求。这篇综合论文深入研究了眼科护理中至关重要的各种交付货物。这些货物包括可生物降解的植入物，逐渐释放药物，用于持续药物输送的不可生物降解植入物，可再填充的工具，允许治疗的灵活性，水凝胶能够保留物质，同时保持眼睛舒适，和精确瞄准眼组织的先进纳米技术设备。在每个货物类别中，我们探索尖端的研究水平方法和FDA批准的方法，全面概述眼科药物输送的现状。特别是,我们对纳米技术工具的关注揭示了基因传递的潜在潜力，细胞疗法给药，并将有源装置直接植入视网膜。这些进步是更有效的关键，个性化，和微创眼科治疗，彻底改变了眼部护理领域。
